高等学校化学学报

高等学校化学学报 ›› 2011, Vol. 32 ›› Issue (11): 2468.

• 研究论文 • 上一篇    下一篇

金属离子调控IRMOF3-sal的发光性质

汪淑华1,张金梅1,陈超1,郑腾飞1,方修忠2   

  1. 1. 南昌大学化学系,
    2.   基础化学实验中心, 南昌 330031
  • 收稿日期:2011-03-23 修回日期:2011-06-20 出版日期:2011-11-10 发布日期:2011-10-14
  • 通讯作者: 汪淑华 E-mail:shwang@ncu.edu.cn
  • 基金资助:

    国家自然科学基金(批准号: 20701018, 21062013)和江西省教育厅基金(批准号:  GJJ08024)资助.

Luminescence of IRMOF3-sal Controled by Metal Ions

WANG Shu-Hua1*, ZHANG Jin-Mei1, CHEN Chao1, ZHENG Teng-Fei1, FANG Xiu-Zhong2   

  1. 1. Department of Chemistry,
    2. Basic Chemistry Experimental Centre, Nanchang University, Nanchang 330031, China
  • Received:2011-03-23 Revised:2011-06-20 Online:2011-11-10 Published:2011-10-14
  • Contact: WANG Shu-Hua E-mail:shwang@ncu.edu.cn
  • Supported by:

    国家自然科学基金(批准号: 20701018, 21062013)和江西省教育厅基金(批准号:  GJJ08024)资助.

PDF (PC)

被引次数

6

摘要： 通过后合成修饰将水杨醛(Salicylaldehyde, sal)锚装在金属-有机框架化合物IRMOF-3上, 捕获不同金属离子得到系列化合物IRMOF3-Msal(M=Mg, Zn, Co, Cd, Ni, Eu, Nd, Pr, Tb); 采用红外光谱、元素分析和X射线粉末衍射对其进行表征, 并对其荧光性质进行了对比研究. 结果表明, IRMOF3-Msal的荧光峰均发生较大蓝移且IRMOF3-Mgsal的荧光强度最大.

关键词: 后合成修饰, 金属-有机框架化合物, 荧光强度

Abstract: A series of IRMOF3-Msal(M=Mg, Zn, Co, Cd, Ni, Eu, Nd, Pr and Tb) was prepared via capturing the metal ions by IRMOF3-sal prepared by postsynthetic modification(PSM) of the isoreticular metal-organic framework(IRMOF-3). We hope it can provide a new approach for the design and preparation of fluorescent porous metal organic frameworks(MOFs). An isoreticular metal-organic framework(IRMOF-3) modified with salicylaldehyde(sal) by postsynthetic modification(PSM) capturing metal ions to yield IRMOF3-Msal(M=Mg, Zn, Co, Cd, Ni, Eu, Nd, Pr, Tb). Their structures were characterized by IR spectra, elemental analysis and  powder X-ray diffraction(XRD). The measurement and analysis of fluorescence spectra indicate that the emission peak of IRMOF3-Msal is blue-shift and IRMOF3-Mgsal displays the strongest relative fluorescence intensity.

Key words: Postsynthetic modification; , Metal-organic framework; , Fluorescence intensity

中图分类号: 

TrendMD: